Is AOD-9604 Legal in Georgia? How to Access It Legally in 2025

What Exactly Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of amino acids 177 through 191 of the human growth hormone (hGH) sequence, with a tyrosine residue added at the N-terminus. Researchers at Monash University originally isolated this fragment because it appeared to retain the lipolytic (fat-releasing) properties of intact hGH without meaningfully stimulating IGF-1 production or promoting tissue growth [1].

Mechanism of Action

In animal studies and early human trials, AOD-9604 appeared to stimulate lipolysis and inhibit lipogenesis through beta-3 adrenergic receptor pathways rather than the classical GH receptor pathway [2]. Because it does not substantially raise IGF-1, investigators theorized it might produce fewer of the adverse effects associated with exogenous hGH, such as insulin resistance, edema, and acromegalic changes.

Clinical Trial History

Metabolic Pharmaceuticals Ltd. Ran the METAOD clinical program through the late 1990s and early 2000s. The Phase IIb trial (N=300, 12 weeks) tested oral AOD-9604 at doses between 1 mg and 9 mg daily in adults with obesity. The trial did not meet its primary weight-loss endpoint against placebo at statistically significant thresholds [3]. A subsequent Phase III program was not completed, and the company did not submit a New Drug Application (NDA) to the FDA. AOD-9604 therefore never received FDA approval for any indication.

The FDA's Generally Recognized as Safe (GRAS) designation was granted for AOD-9604 as a food ingredient in 2014, a point frequently cited in marketing materials. That designation applies specifically to use as a food additive at specified concentrations. It does not extend to injectable or subcutaneous pharmaceutical use, and it does not constitute drug approval [4].

Federal Legal Status: What the FDA Actually Says

AOD-9604 is not approved by the FDA as a drug. That single fact drives every downstream legal question about access in Georgia.

The Bulk Substances List and 503B Restrictions

Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), outsourcing facilities (high-volume, hospital-supply compounders) may prepare drugs from bulk active pharmaceutical ingredients only if those substances appear on an FDA-approved bulk substances list [5]. The FDA has published a list of bulk substances that present difficulties for compounding, substances that raise safety concerns or for which the agency has not found adequate evidence of clinical need. AOD-9604 was nominated for review and, as of 2025, sits in a category that effectively prevents 503B outsourcing facilities from compounding it for distribution without individual prescriptions [6].

The practical consequence: large-scale compounding operations that supply clinics with prefilled vials cannot legally produce AOD-9604 under the 503B framework.

503A Compounding Pharmacies and Individual Prescriptions

Section 503A of the FD&C Act governs traditional compounding pharmacies that prepare medications for individual patients in response to a valid prescription [7]. These pharmacies are not subject to the same bulk-substance restrictions as 503B facilities, provided several conditions are met:

• The compounded preparation is not essentially a copy of an FDA-approved drug.
• The prescription is patient-specific and written by a licensed practitioner with a valid patient-prescriber relationship.
• The pharmacy is licensed in the state where the patient resides or where the prescription is dispensed.
• The ingredients used meet USP or NF monograph standards where applicable.

Because no FDA-approved drug product contains AOD-9604 as its active ingredient, a 503A pharmacy can, in principle, compound it without running into the "copy" prohibition. This is the legal channel through which most clinic-dispensed AOD-9604 currently moves in the United States.

Is This a Gray Area?

Yes. The FDA has the authority to place substances on a "difficult to compound" list that would restrict 503A pharmacies as well, though the process for that list differs from the 503B process [8]. The agency has not completed that rulemaking for AOD-9604 as of this writing. Clinicians and pharmacies operating in this space should monitor FDA guidance updates. The regulatory picture could shift.

Georgia State Law and Pharmacy Board Rules

Georgia does not have a state-level statute that specifically names AOD-9604 or classifies it as a controlled substance. The relevant state framework is the Georgia Pharmacy Practice Act (O.C.G.A. Title 26, Chapter 4) and the rules of the Georgia State Board of Pharmacy [9].

Georgia Board of Pharmacy Requirements for Compounders

The Georgia State Board of Pharmacy requires that any pharmacy compounding sterile preparations, including injectable peptides, hold a valid sterile compounding permit and comply with USP Chapter 797 standards for sterile compounding [10]. USP 797 sets environmental monitoring, beyond-use dating, personnel training, and quality testing requirements for sterile preparations. A pharmacy compounding AOD-9604 for subcutaneous injection must meet these standards.

Patients and prescribers should verify that any pharmacy dispensing injectable AOD-9604 in Georgia holds a current sterile compounding permit from the Georgia State Board of Pharmacy. The Board's license verification portal allows public lookup by pharmacy name or license number.

The Prescriber-Patient Relationship Requirement

Georgia's medical practice act (O.C.G.A. § 43-34-21) requires that a prescription be issued within the context of a valid prescriber-patient relationship [11]. Telehealth-initiated prescriptions are permissible under Georgia law, including after the telehealth flexibilities extended during the COVID-19 public health emergency. However, prescribing AOD-9604 solely on the basis of an online questionnaire without a clinical evaluation would not satisfy this standard. A thorough review of medical history, weight history, current medications, and relevant labs is expected.

No Georgia-Specific AOD-9604 Ban

Georgia has not enacted a statute banning AOD-9604 by name or by class. Peptides that are not controlled substances under the federal Controlled Substances Act and are not on Georgia's controlled substances schedule (O.C.G.A. § 16-13-21 et seq.) can be legally prescribed and dispensed through the compounding pathway described above [12]. AOD-9604 is not listed on Georgia's controlled substance schedule as of July 2025.

How to Get AOD-9604 Legally in Georgia

The legal access pathway has four sequential steps. Each step must be completed in order.

Step 1: Clinical Evaluation by a Licensed Georgia Prescriber

A physician, physician assistant, or nurse practitioner licensed in Georgia must evaluate you and determine that AOD-9604 is an appropriate therapeutic option. The evaluation should include BMI measurement, weight history, prior attempts at weight management, relevant metabolic labs (fasting glucose, HbA1c, lipid panel, thyroid function), and a medication review to screen for contraindications.

Relevant context: the 2023 American Endocrine Society Clinical Practice Guideline on obesity pharmacotherapy recommends using FDA-approved agents as first-line pharmacotherapy for obesity in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity [13]. AOD-9604 is not among those agents. A clinician prescribing it should document the clinical rationale, particularly if FDA-approved alternatives like semaglutide 2.4 mg (Wegovy) have been tried, are contraindicated, or are unavailable due to supply or cost.

To put the evidence gap in perspective: In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [14]. No completed Phase III trial has shown comparable efficacy for AOD-9604.

Step 2: Valid Prescription Issued to a Licensed 503A Pharmacy

The prescriber must write a patient-specific prescription for AOD-9604 and direct it to a 503A-licensed compounding pharmacy that holds a Georgia sterile compounding permit or is licensed to ship into Georgia. The prescription must specify the formulation (concentration, volume, route of administration, and dosing schedule).

Step 3: Pharmacy Verification

Before accepting a dispensed vial, the patient or clinic should verify:

• The pharmacy holds a current 503A license in its home state.
• The pharmacy holds a sterile compounding permit and complies with USP 797.
• The pharmacy is registered to ship to Georgia (out-of-state pharmacies must register with the Georgia Board).
• A certificate of analysis (CoA) from an independent third-party laboratory is available for the batch.

Third-party testing matters because compounded peptides are not subject to FDA batch-release testing. A CoA should confirm identity (by HPLC), purity (98% or higher is a common standard), and sterility of the specific lot [15].

Step 4: Administration and Monitoring

AOD-9604 is typically administered subcutaneously. Dosing protocols used in the METAOD trials ranged from 1 mg to 9 mg daily (oral route in those trials). Injectable compounded preparations used in clinical practice are generally dosed between 250 mcg and 500 mcg per day subcutaneously, though no FDA-approved dosing protocol exists [16]. The prescribing clinician determines the dose based on clinical judgment.

Monitoring should include periodic weight, waist circumference, fasting metabolic labs, and assessment of any injection-site reactions. The long-term safety profile of injectable AOD-9604 in humans has not been established in large randomized trials.

The framework below summarizes the legal access pathway and the regulatory checkpoints that distinguish compliant access from non-compliant gray-market acquisition.

| Step | Requirement | Regulatory Basis | |------|-------------|-----------------| | Clinical evaluation | Valid prescriber-patient relationship | O.C.G.A. § 43-34-21 | | Prescription | Patient-specific, written by GA-licensed provider | FD&C Act § 503A; GA Pharmacy Practice Act | | Pharmacy | 503A licensed, sterile compounding permit, GA-registered | USP 797; GA Board of Pharmacy | | Product | CoA confirming identity, purity, sterility | FDA compounding guidance; USP 797 | | Administration | Supervised or patient-directed with clinical monitoring | Medical practice standards |

What Is Not Legal: Common Pitfalls

Ordering Online Without a Prescription

Purchasing AOD-9604 from domestic or international research chemical websites without a prescription violates 21 U.S.C. § 331, which prohibits the introduction of unapproved new drugs into interstate commerce [17]. Products labeled "for research use only" or "not for human use" do not become legal for human use by virtue of that label if they are in fact sold for human administration.

Importing From Foreign Sources

Personal importation of unapproved drug substances is prohibited under the FD&C Act. The FDA's Personal Importation Policy provides limited discretionary enforcement for FDA-approved drugs obtained abroad, but that discretion does not extend to unapproved drug substances like AOD-9604 [18].

Using a 503B Outsourcing Facility

As discussed above, the current regulatory posture makes it difficult for 503B outsourcing facilities to supply AOD-9604. Clinics that obtain it from a 503B source should review the current FDA bulk substances list before proceeding [6].

Clinical Context: Who Is a Candidate?

Candidates most commonly considered for AOD-9604 in clinical practice are adults who:

• Have a BMI of 27 or higher with at least one metabolic comorbidity, or a BMI of 30 or higher.
• Have had an inadequate response to lifestyle modification alone.
• Cannot use or do not wish to use GLP-1 receptor agonists due to tolerability issues (nausea, vomiting, gastroparesis risk) or contraindications such as personal or family history of medullary thyroid carcinoma.
• Are not candidates for bariatric surgery or have declined it.

The evidence supporting this use is limited. The Phase IIb METAOD trial data showed modest and statistically non-significant weight loss differences at most dose levels tested [3]. Clinicians should communicate this evidence gap clearly to patients before prescribing. The Endocrine Society's 2023 guideline explicitly states: "We recommend against using medications not approved for obesity treatment for this indication when approved medications are available and appropriate." [13]

Patients should understand that AOD-9604 is not a substitute for proven therapies when those therapies are accessible and tolerated.

Georgia Telehealth and AOD-9604

Georgia permits telehealth prescribing, including for controlled substances subject to DEA rules, and for non-controlled substances with even fewer restrictions [19]. Because AOD-9604 is not a controlled substance, a telehealth prescriber licensed in Georgia may issue a prescription for it after a synchronous (real-time video or phone) evaluation that satisfies the prescriber-patient relationship requirement.

Asynchronous-only (questionnaire-based, no real-time interaction) prescribing for this indication is legally and ethically questionable. Several state medical boards have moved to restrict pure-asynchronous prescribing for weight-management compounds. Georgia prescribers should consult current Georgia Composite Medical Board guidance before prescribing via asynchronous telehealth [20].

Safety Considerations

AOD-9604 has a limited human safety dataset. The METAOD Phase IIb trial reported no serious adverse events attributable to the compound at oral doses up to 9 mg daily over 12 weeks [3]. Injectable formulations in compounding pharmacy preparations have not been studied in large randomized controlled trials. Known theoretical risks include:

• Injection-site reactions (erythema, induration, bruising).
• Immune sensitization to the peptide sequence.
• Unknown long-term effects given the absence of Phase III completion.

The FDA's position on compounded drugs is that they lack the safety and efficacy data that FDA-approved products carry [4]. Patients accepting a compounded AOD-9604 preparation should receive a written informed consent document acknowledging these limitations.